493 related articles for article (PubMed ID: 26514402)
1. Purinergic contribution to amyotrophic lateral sclerosis.
Volonté C; Apolloni S; Parisi C; Amadio S
Neuropharmacology; 2016 May; 104():180-93. PubMed ID: 26514402
[TBL] [Abstract][Full Text] [Related]
2. Purinergic signalling in brain ischemia.
Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
[TBL] [Abstract][Full Text] [Related]
3. CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17.
Fumagalli M; Lecca D; Abbracchio MP
Neuropharmacology; 2016 May; 104():82-93. PubMed ID: 26453964
[TBL] [Abstract][Full Text] [Related]
4. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
[TBL] [Abstract][Full Text] [Related]
5. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis.
Gandelman M; Peluffo H; Beckman JS; Cassina P; Barbeito L
J Neuroinflammation; 2010 Jun; 7():33. PubMed ID: 20534165
[TBL] [Abstract][Full Text] [Related]
6. ATPergic signalling during seizures and epilepsy.
Engel T; Alves M; Sheedy C; Henshall DC
Neuropharmacology; 2016 May; 104():140-53. PubMed ID: 26549853
[TBL] [Abstract][Full Text] [Related]
7. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
Burnstock G
Neuropharmacology; 2016 May; 104():4-17. PubMed ID: 26056033
[TBL] [Abstract][Full Text] [Related]
8. Purinergic mechanisms in neuroinflammation: An update from molecules to behavior.
Beamer E; Gölöncsér F; Horváth G; Bekő K; Otrokocsi L; Koványi B; Sperlágh B
Neuropharmacology; 2016 May; 104():94-104. PubMed ID: 26384652
[TBL] [Abstract][Full Text] [Related]
9. Rethinking purinergic concepts and updating the emerging role of P2X7 and P2X4 in amyotrophic lateral sclerosis.
Volonté C; Amadio S
Neuropharmacology; 2022 Dec; 221():109278. PubMed ID: 36202258
[TBL] [Abstract][Full Text] [Related]
10. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis.
D'Ambrosi N; Finocchi P; Apolloni S; Cozzolino M; Ferri A; Padovano V; Pietrini G; Carrì MT; Volonté C
J Immunol; 2009 Oct; 183(7):4648-56. PubMed ID: 19734218
[TBL] [Abstract][Full Text] [Related]
11. Purinergic receptors in psychiatric disorders.
Krügel U
Neuropharmacology; 2016 May; 104():212-25. PubMed ID: 26518371
[TBL] [Abstract][Full Text] [Related]
12. ALS: focus on purinergic signalling.
Volonté C; Apolloni S; Carrì MT; D'Ambrosi N
Pharmacol Ther; 2011 Oct; 132(1):111-22. PubMed ID: 21704075
[TBL] [Abstract][Full Text] [Related]
13. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
Apolloni S; Parisi C; Pesaresi MG; Rossi S; Carrì MT; Cozzolino M; Volonté C; D'Ambrosi N
J Immunol; 2013 May; 190(10):5187-95. PubMed ID: 23589615
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.
Liu J; Prell T; Stubendorff B; Keiner S; Ringer T; Gunkel A; Tadic V; Goldhammer N; Malci A; Witte OW; Grosskreutz J
Neurosci Lett; 2016 Sep; 630():77-83. PubMed ID: 27453058
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis.
Amadio S; Apolloni S; D'Ambrosi N; Volonté C
J Neurochem; 2011 Mar; 116(5):796-805. PubMed ID: 21214557
[TBL] [Abstract][Full Text] [Related]
16. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
17. Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events.
Apolloni S; Montilli C; Finocchi P; Amadio S
FEBS J; 2009 Jan; 276(2):354-64. PubMed ID: 19076216
[TBL] [Abstract][Full Text] [Related]
18. P2Y(12) receptor on the verge of a neuroinflammatory breakdown.
Amadio S; Parisi C; Montilli C; Carrubba AS; Apolloni S; Volonté C
Mediators Inflamm; 2014; 2014():975849. PubMed ID: 25180027
[TBL] [Abstract][Full Text] [Related]
19. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives.
Cieślak M; Roszek K; Wujak M
Purinergic Signal; 2019 Mar; 15(1):1-15. PubMed ID: 30430356
[TBL] [Abstract][Full Text] [Related]
20. Purinergic receptors in embryonic and adult neurogenesis.
Oliveira Á; Illes P; Ulrich H
Neuropharmacology; 2016 May; 104():272-81. PubMed ID: 26456352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
